This is a study for patients diagnosed with Her2 negative breast cancer. It is looking at the effectiveness and safety of doxorubicin plus cyclophosphamide followed by weekly paclitaxel plus trastuzumab and pertuzumab before surgery.
Contact phone
Carolyn Krahulik | 517.364.2811
Contact email
cancerclinicaltrials@sparrow.org
Principal investigator
Dr. Gordan Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Breast
Webform